A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

A federal judge ended compounding pharmacies’ ability to make copies of the weight loss and diabetes drugs Zepbound and ...

Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs.

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer continued to warn users to not trust billionaires. His ...

The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more af ...

As part of the deal, which will be completed later this year, the Chicago-based pharmacy chain will sell its VillageMD unit. Other pharmaceutical news is about Cost Plus Drug Co., Eli Lilly, and more.